Don’t reject potential of vitamins to cut heart disease risk because of ‘inappropriate’ clinical trials: Review

By Stephen Daniells

- Last updated on GMT

Don’t reject potential of vitamins to cut heart disease risk because of ‘inappropriate’ clinical trials: Review

Related tags Vitamin Folic acid

Conclusions from clinical trials that B and E vitamins may be ineffective for reducing the risk of heart disease are inappropriate and the vitamins should not be rejected, says a new review of the evidence.

A new review in the PubMed-listed journal Cardiovascular Therapeutics​found that many of the clinical trials examining if supplementation with B vitamins or vitamin E could benefit cardiovascular and cerebrovascular health neglected to consider confounding factors, such as the use of medication.

This led to a bias and inappropriate conclusions, state Balazs Debreceni from the University of Pecs in Hungary and Laszlo Debreceni from the Heart Disease Research Foundation in Brooklyn, New York.

 “From the large vitamin trials, no conclusions along the lines of ‘B vitamin supplements cannot currently be recommended for the prevention of CVD events’ or ‘vitamin E was associated with an increased risk of hemorrhagic stroke’ can be drawn because the results were determined from inappropriate trial settings, and—in the latter case—can be accounted for by the combined action of vitamin E plus aspirin, since antiplatelet and anticoagulant effects are accumulative when taken in combination,”​ wrote Debreceni and Debreceni.

“We take the view that (1) the B- and E-vitamin prevention therapy can work in the primary prevention, and (2) the large vitamin trials did not have power to settle the debate on the effectiveness of vitamin substitution in the secondary prevention of the cardiovascular diseases.”


The potential role of B vitamins in heart health, by reducing levels of the amino acid homocysteine reported to increase the risk of cardiovascular disease, is controversial.

Epidemiological studies have linked increased blood levels of the amino acid homocysteine to an increased risk of cardiovascular disease (CVD). It has been suggested that by lowering the levels of homocysteine in the blood with B-vitamins, people could cut the risk of CVD.

However, clinical trials including participants at risk of, or already suffering from, cardiovascular disease have produced null results, with some experts arguing that short term B vitamin supplementation should not be expected to reverse the long-term development of heart disease.

In 2009 a prestigious Cochrane review concluded in that supplements of B6, B12 or folate do not affect cardiovascular health, despite lowering homocysteine levels. The review included data from eight randomized controlled trials equivalent to 24,210 participants.

New review

Debreceni and Debreceni analyzed eight B vitamin and four E vitamin trials and found that “possible factors implicated in the failure of vitamin therapies included inappropriate designs.

“The protocols neglected an essential fact: that the impact of some confounding factors, such as concomitant use of statins, acetylsalicylic acid, folic acid, and other drugs, might have led to bias and an inappropriate interpretation of the data.”

“The cardiovascular protective and preventive effects of statins and aspirin might have reduced or abolished the possibility of observing a difference in the number of events between the vitamin and placebo groups for the clinical endpoints.

“We concluded that the vitamin preventive effect on cardiovascular disease may not be rejected in reference to the negative trial evidence.”

Other perspective

Another interpretation of the null findings from clinical trials has been proposed by several different sources, is related to the use of nutrients in diseased populations to try to reverse a lifetime of poor lifestyle.

Criticism has also focused on the design of the trials – some commentators have stated that a set dose of a nutrient for a select period, is an inappropriate way to evaluate the potential of nutrients to influence health and wellness.

Source: Cardiovascular Therapeutics
August 2012, Volume 30, Issue 4, pages 227–233, doi: 10.1111/j.1755-5922.2011.00266.x
“Why Do Homocysteine-Lowering B Vitamin and Antioxidant E Vitamin Supplementations Appear To Be Ineffective in the Prevention of Cardiovascular Diseases?”
Authors: B. Debreceni, L. Debreceni

Related news

Show more

Related products

show more

Krill oil supports six key areas of healthy aging

Krill oil supports six key areas of healthy aging

Content provided by Aker BioMarine | 14-Feb-2024 | White Paper

The global population is getting older—according to WHO by 2050 the world’s population over 60 years will double and the population above 80 years will...

Latest Research Findings on Omega-3s for Heart Health

Latest Research Findings on Omega-3s for Heart Health

Content provided by GC Rieber VivoMega™ | 12-Feb-2024 | White Paper

According to Grandview Research, the global omega-3 market is a $2.62 billion market and is one of the fastest-growing segments in the dietary supplement...

Kaneka Ubiquinol® and Preconception Health

Kaneka Ubiquinol® and Preconception Health

Content provided by Kaneka Nutrients – Manufacturer and Supplier of Kaneka Ubiquinol® | 02-Feb-2024 | White Paper

An ally in the fight against oxidative stress, Kaneka Ubiquinol® offers antioxidant support for men and women concerned about reproductive health.

Related suppliers


Big Pharma controls studies

Posted by Chick Bowers,

-We must ignore most studies published on the
clinical effects of supplements on health.
Most of these studies are conducted with the
typical over the counter supplements ,which are
sourced from artificial forms of the vitamin, thus
treated by the body as a toxin or invader.

They would never have tested against a quality
supplement sourced from whole food ,which would
give the proper result.

Report abuse

Clinical Trials on the value Nutrition.

Posted by Harry,

Agreed? Most Clinical trials that try to discredit nutrition are inappropriate as the application of use in best practice and over the counter proves.

Report abuse

Follow us


View more